Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160142 | 0.90 | PPARG (0.50) | BCL2L1MCL1PTGER4AGTR2PPARG | |
| SCHEMBL1160209 | 0.89 | PPARG (0.47) | BCL2L1MCL1AGTR2PPARGMEN1 | |
| SCHEMBL1160112 | 0.88 | PPARG (0.61) | AGTR2PPARGAGTR1 | |
| SCHEMBL6170111 | 0.88 | PPARG (0.60) | AGTR2PPARGAGTR1 | |
| SCHEMBL1160057 | 0.87 | AGTR2 (0.47) | BCL2L1MCL1PTGER4AGTR2PPARG | |
| SCHEMBL7591162 | 0.87 | AGTR2 (0.62) | AGTR2PPARGAGTR1 | |
| SCHEMBL1160063 | 0.86 | PPARG (0.50) | PTGER4AGTR2PPARGAGTR1 | |
| SCHEMBL1160341 | 0.86 | HDAC1 (0.55) | BCL2L1MCL1PTGER4AGTR2PPARG | |
| SCHEMBL6308656 | 0.85 | PTGER4 (0.46) | BCL2L1MCL1PTGER4PPARG | |
| SCHEMBL1159879 | 0.85 | AGTR2 (0.58) | AGTR2PPARGAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563589-B2 | Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma | SAMEEVE CORP | 2013-10-22 | — | — | US | disclosed |
| EP-2459192-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | Aestus Therapeutics, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014600-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | BCL2L1 636/4885MCL1 7/4885PTGER4 3064/4885 |
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | BCL2L1 1225/4885MCL1 3377/4885PTGER4 37/4885 |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | BCL2L1 1225/4885MCL1 3377/4885PTGER4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.